SCHEMBL6504098

SCHEMBL6504098

Cc1cccc(NC(=O)Nc2c(Cl)cccc2Cl)c1C(=O)O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPM4 Q8TD43 1/20 0.56
FABP3 P05413 1/20 0.56
FABP4 P15090 1/20 0.56
KDM4E B2RXH2 2/20 0.50
NPSR1 Q6W5P4 1/20 0.48
PYGL P06737 3/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
TRPV1 Q8NER1 2/20 0.47
MAPT P10636 2/20 0.47
LMNA P02545 2/20 0.47
CXCL8 P10145 1/20 0.46
PTGS2 P35354 1/20 0.46
ALDH1A1 P00352 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
L3MBTL1 Q9Y468 1/20 0.45
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
CRHBP P24387 1/20 0.44
CRHR2 Q13324 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6500776 0.80 DDX3X (0.64) KDM4EMEN1KMT2AMAPTLMNA
SCHEMBL6498063 0.79 RAB9A (0.65) KDM4EMEN1KMT2ATRPV1MAPT
SCHEMBL5194281 0.77 KDM4E (0.62) FABP3FABP4KDM4EMEN1KMT2A
SCHEMBL3419678 0.77 NPSR1 (0.59) NPSR1MEN1KMT2AMAPTLMNA
SCHEMBL10490004 0.76 KDM4E (0.56) TRPM4FABP3FABP4KDM4EMEN1
SCHEMBL2624008 0.76 HPGD (0.63) TRPM4FABP3FABP4KDM4EMEN1
SCHEMBL31606982 0.76 FABP4 (0.70) TRPM4FABP3FABP4KDM4EMEN1
SCHEMBL4358635 0.76 TRPV1 (0.52) KDM4EPYGLMEN1KMT2ATRPV1
SCHEMBL6497268 0.76 ITGB3 (0.53) TRPM4FABP3FABP4KDM4EMEN1
SCHEMBL6504061 0.76 KDM4E (0.52) TRPM4FABP3FABP4KDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050032793-A1 2-amino-benzoxazinones for the treatment of viral infections G.D. SEARLE & CO. (US) 2005-02-10 US disclosed
US-6683077-B2 4H-3,1-BENZOXAZIN-4-ONE COMPOUNDS OF GIVEN FORMULA; HERPES INFECTIONS; ASSEMBLIN PROTEASE INHIBITORS G.D. SEARLE & CO. 2004-01-27 US disclosed
US-20030022895-A1 2-Amino-benzoxazinones for the treatment of viral infections G.D. SEARLE & CO. 2003-01-30 US disclosed
US-6380189-B1 FOR TREATING HERPES-RELATED DISORDERS G.D. SEARLE & CO. 2002-04-30 US disclosed
EP-0828721-B1 2-AMINO-BENZOXAZINONES FOR THE TREATMENT OF VIRAL INFECTIONS SEARLE & CO (US) 2001-11-14 EP disclosed
EP-1122245-A2 2-Amino-benzoxazinones for the treatment of viral infections G.D. Searle & Co. (US) 2001-08-08 EP disclosed
US-5985872-A THERAPEUTIC TREATMENT OF HERPES VIRAL INFECTION G.D. SEARLE & CO. (US) 1999-11-16 US disclosed
EP-0828721-A1 2-AMINO-BENZOXAZINONES FOR THE TREATMENT OF VIRAL INFECTIONS G.D. SEARLE & CO. (US) 1998-03-18 EP disclosed
WO-1996037485-A1 2-AMINO-BENZOXAZINONES FOR THE TREATMENT OF VIRAL INFECTIONS G.D. SEARLE & CO. (US) 1996-11-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030022895-A1 2-Amino-benzoxazinones for the treatment of viral infections IFNAR1, IL4I1, HAX1 TRPM4 402/4885FABP3 3500/4885FABP4 2616/4885
US-20050032793-A1 2-amino-benzoxazinones for the treatment of viral infections IFNAR1, IL4I1, ACE2 TRPM4 1098/4885FABP3 3844/4885FABP4 3819/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.